Xeloda: Oral Chemotherapy for Colorectal and Breast Cancer - Evidence-Based Review

Product Description: Xeloda is an oral chemotherapeutic agent, specifically a prodrug of 5-fluorouracil (5-FU). It is classified as an antimetabolite and is indicated for the adjuvant treatment of patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor, and for the treatment of patients with metastatic colorectal cancer and metastatic breast cancer. Its unique oral administration offers a distinct advantage over traditional intravenous 5-FU regimens, enabling a more patient-centric approach to cancer care.